David E. Cummings
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David E. Cummings has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Francesco Rubino
Department of Surgery, King’s College London, London, UK
5 shared publications Joost Overduin
University of Washington School of Medicine, Seattle, Washington; and Veterans Affairs Puget Sound Health Care System Seattle, Washington
5 shared publicationsRicardo V. Cohen
Center for Diabetes and Obesity, Oswaldo Cruz Hospital, São Paulo, Brazil
5 shared publicationsPhilip R. Schauer
Cleveland Clinic Foundation, Cleveland, Ohio, USA
4 shared publicationsR. Scott Frayo
University of Washington School of Medicine, Seattle, Washington; and Veterans Affairs Puget Sound Health Care System Seattle, Washington
4 shared publicationsDavid M. Nathan
Harvard Medical School, Boston, MA, USA
3 shared publications
Latest Publications
- 1 September 2019
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 15 (9) , 1431-1438
Banded versus nonbanded laparoscopic sleeve gastrectomy: 5-year outcomes
- 1 September 2019
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 15 (9) , 1431-1438
Banded versus nonbanded laparoscopic sleeve gastrectomy: 5-year outcomes
- Open Access
- 9 December 2017
- Published by Springer Nature in Diabetologia
- Vol. 61 (2) , 257-264
Metabolic surgery for the treatment of type 2 diabetes in obese individuals
Several bariatric operations originally designed to promote weight loss have been found to powerfully treat type 2 diabetes, causing remission in most cases, through diverse mechanisms additional to the secondary consequences of weight loss. These observations have prompted consideration of such operations as ‘metabolic surgery’, used expressly to treat diabetes, including among patients who are only mildly obese or merely overweight. Large, long-term observational studies consistently demonstrate that bariatric/metabolic surgery is associated with reductions in all cardiovascular risk factors, actual cardiovascular events, microvascular diabetes complications, cancer and death. Numerous recent randomised clinical trials, directly comparing various surgical vs non-surgical interventions for diabetes, uniformly demonstrate the former to be superior for improvements in all glycaemic variables, as well as other metabolic endpoints. These benefits are similar among individuals with type 2 diabetes and a preoperative BMI of 30–35 kg/m2 compared with traditional bariatric surgery patients with a BMI >35 kg/m2. The safety profiles of modern laparoscopic bariatric/metabolic operations are similar to those of elective laparoscopic hysterectomy and knee arthroplasty. However, more evidence regarding the risks, benefits and costs of surgery is needed from very long-term (>5 year) randomised clinical trials powered to observe ‘hard’ clinical endpoints following the operations most commonly used today. Given the efficacy, safety and cost-effectiveness of metabolic surgery, the second Diabetes Surgery Summit (DSS-II) consensus conference recently placed surgery squarely within the overall diabetes treatment algorithm, recommending consideration of this approach for patients with inadequately controlled diabetes and a BMI as low as 30 kg/m2, or 27.5 kg/m2 for Asian individuals. These new guidelines have been formally ratified by 53 leading diabetes and surgery societies worldwide. Given this broad level of endorsement, we feel that the DSS-II recommendations should now replace the outdated National Institutes of Health (NIH) suggestions that have governed bariatric surgery practice and insurance compensation worldwide since 1991.
- 9 December 2017
- Published by Springer Nature in Diabetologia
- Vol. 61 (2) , 257-264
Open AccessMetabolic surgery for the treatment of type 2 diabetes in obese individuals
Several bariatric operations originally designed to promote weight loss have been found to powerfully treat type 2 diabetes, causing remission in most cases, through diverse mechanisms additional to the secondary consequences of weight loss. These observations have prompted consideration of such operations as ‘metabolic surgery’, used expressly to treat diabetes, including among patients who are only mildly obese or merely overweight. Large, long-term observational studies consistently demonstrate that bariatric/metabolic surgery is associated with reductions in all cardiovascular risk factors, actual cardiovascular events, microvascular diabetes complications, cancer and death. Numerous recent randomised clinical trials, directly comparing various surgical vs non-surgical interventions for diabetes, uniformly demonstrate the former to be superior for improvements in all glycaemic variables, as well as other metabolic endpoints. These benefits are similar among individuals with type 2 diabetes and a preoperative BMI of 30–35 kg/m2 compared with traditional bariatric surgery patients with a BMI >35 kg/m2. The safety profiles of modern laparoscopic bariatric/metabolic operations are similar to those of elective laparoscopic hysterectomy and knee arthroplasty. However, more evidence regarding the risks, benefits and costs of surgery is needed from very long-term (>5 year) randomised clinical trials powered to observe ‘hard’ clinical endpoints following the operations most commonly used today. Given the efficacy, safety and cost-effectiveness of metabolic surgery, the second Diabetes Surgery Summit (DSS-II) consensus conference recently placed surgery squarely within the overall diabetes treatment algorithm, recommending consideration of this approach for patients with inadequately controlled diabetes and a BMI as low as 30 kg/m2, or 27.5 kg/m2 for Asian individuals. These new guidelines have been formally ratified by 53 leading diabetes and surgery societies worldwide. Given this broad level of endorsement, we feel that the DSS-II recommendations should now replace the outdated National Institutes of Health (NIH) suggestions that have governed bariatric surgery practice and insurance compensation worldwide since 1991.
- 12 December 2016
- Published by Springer Nature in Obesity Surgery
- Vol. 27 (1) , 2-21
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations
Despite growing evidence that bariatric/metabolic surgery powerfully improves type 2 diabetes (T2D), existing diabetes treatment algorithms do not include surgical options.
- 12 December 2016
- Published by Springer Nature in Obesity Surgery
- Vol. 27 (1) , 2-21
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations
Despite growing evidence that bariatric/metabolic surgery powerfully improves type 2 diabetes (T2D), existing diabetes treatment algorithms do not include surgical options.
- Open Access
- 11 October 2016
- Published by American Diabetes Association in Diabetes Care
- Vol. 39 (11) , e202-e203
Response to Comment on Rubino et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care 2016;39:861–877
On behalf of the 48 coauthors from our article reporting the findings and recommendations of the 2nd Diabetes Surgery Summit (DSS-II) (1), we sincerely thank Aberle and Göke (2) for their insightful comments about the consideration of sodium–glucose cotransporter 2 (SGLT2) inhibitors to treat type 2 diabetes (T2D) shortly after bariatric/metabolic surgery. The DSS-II was a consensus development conference, culminating a year-long effort to generate new guidelines for the use of “bariatric” operations to expressly treat T2D (i.e., “metabolic surgery”), including among patients not obese enough to qualify for surgery according to traditional BMI-based criteria. Among our 32 position statements, which all had a high consensus rate, one recommendation endorsed the usage …
- 11 October 2016
- Published by American Diabetes Association in Diabetes Care
- Vol. 39 (11) , e202-e203
Open AccessResponse to Comment on Rubino et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care 2016;39:861–877
On behalf of the 48 coauthors from our article reporting the findings and recommendations of the 2nd Diabetes Surgery Summit (DSS-II) (1), we sincerely thank Aberle and Göke (2) for their insightful comments about the consideration of sodium–glucose cotransporter 2 (SGLT2) inhibitors to treat type 2 diabetes (T2D) shortly after bariatric/metabolic surgery. The DSS-II was a consensus development conference, culminating a year-long effort to generate new guidelines for the use of “bariatric” operations to expressly treat T2D (i.e., “metabolic surgery”), including among patients not obese enough to qualify for surgery according to traditional BMI-based criteria. Among our 32 position statements, which all had a high consensus rate, one recommendation endorsed the usage …
- 7 July 2016
- Published by Springer Nature in Diabetologia
- Vol. 59 (9) , 2042-2044
Diabetes remission off medications is not a suitable endpoint for comparing bariatric/metabolic surgery with pharmacotherapy. Reply to Halpern B, Cercato C, Mancini MC [letter]
- 7 July 2016
- Published by Springer Nature in Diabetologia
- Vol. 59 (9) , 2042-2044
Diabetes remission off medications is not a suitable endpoint for comparing bariatric/metabolic surgery with pharmacotherapy. Reply to Halpern B, Cercato C, Mancini MC [letter]
- 1 July 2016
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 12 (6) , 1144-1162
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
- 1 July 2016
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 12 (6) , 1144-1162
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
- 1 July 2016
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 12 (6) , 1199-1205
Changes of insulin sensitivity and secretion after bariatric/metabolic surgery
- 1 July 2016
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 12 (6) , 1199-1205
Changes of insulin sensitivity and secretion after bariatric/metabolic surgery
- Top Cited Papers
- 13 May 2016
- Published by American Diabetes Association in Diabetes Care
- Vol. 39 (6) , 861-877
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
BACKGROUND Despite growing evidence that bariatric/metabolic surgery powerfully improves type 2 diabetes (T2D), existing diabetes treatment algorithms do not include surgical options. AIM The 2nd Diabetes Surgery Summit (DSS-II), an international consensus conference, was convened in collaboration with leading diabetes organizations to develop global guidelines to inform clinicians and policymakers about benefits and limitations of metabolic surgery for T2D. METHODS A multidisciplinary group of 48 international clinicians/scholars (75% nonsurgeons), including representatives of leading diabetes organizations, participated in DSS-II. After evidence appraisal (MEDLINE [1 January 2005–30 September 2015]), three rounds of Delphi-like questionnaires were used to measure consensus for 32 data-based conclusions. These drafts were presented at the combined DSS-II and 3rd World Congress on Interventional Therapies for Type 2 Diabetes (London, U.K., 28–30 September 2015), where they were open to public comment by other professionals and amended face-to-face by the Expert Committee. RESULTS Given its role in metabolic regulation, the gastrointestinal tract constitutes a meaningful target to manage T2D. Numerous randomized clinical trials, albeit mostly short/midterm, demonstrate that metabolic surgery achieves excellent glycemic control and reduces cardiovascular risk factors. On the basis of such evidence, metabolic surgery should be recommended to treat T2D in patients with class III obesity (BMI ≥40 kg/m2) and in those with class II obesity (BMI 35.0–39.9 kg/m2) when hyperglycemia is inadequately controlled by lifestyle and optimal medical therapy. Surgery should also be considered for patients with T2D and BMI 30.0–34.9 kg/m2 if hyperglycemia is inadequately controlled despite optimal treatment with either oral or injectable medications. These BMI thresholds should be reduced by 2.5 kg/m2 for Asian patients. CONCLUSIONS Although additional studies are needed to further demonstrate long-term benefits, there is sufficient clinical and mechanistic evidence to support inclusion of metabolic surgery among antidiabetes interventions for people with T2D and obesity. To date, the DSS-II guidelines have been formally endorsed by 45 worldwide medical and scientific societies. Health care regulators should introduce appropriate reimbursement policies.
- 13 May 2016
- Published by American Diabetes Association in Diabetes Care
- Vol. 39 (6) , 861-877
Top Cited PapersMetabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
BACKGROUND Despite growing evidence that bariatric/metabolic surgery powerfully improves type 2 diabetes (T2D), existing diabetes treatment algorithms do not include surgical options. AIM The 2nd Diabetes Surgery Summit (DSS-II), an international consensus conference, was convened in collaboration with leading diabetes organizations to develop global guidelines to inform clinicians and policymakers about benefits and limitations of metabolic surgery for T2D. METHODS A multidisciplinary group of 48 international clinicians/scholars (75% nonsurgeons), including representatives of leading diabetes organizations, participated in DSS-II. After evidence appraisal (MEDLINE [1 January 2005–30 September 2015]), three rounds of Delphi-like questionnaires were used to measure consensus for 32 data-based conclusions. These drafts were presented at the combined DSS-II and 3rd World Congress on Interventional Therapies for Type 2 Diabetes (London, U.K., 28–30 September 2015), where they were open to public comment by other professionals and amended face-to-face by the Expert Committee. RESULTS Given its role in metabolic regulation, the gastrointestinal tract constitutes a meaningful target to manage T2D. Numerous randomized clinical trials, albeit mostly short/midterm, demonstrate that metabolic surgery achieves excellent glycemic control and reduces cardiovascular risk factors. On the basis of such evidence, metabolic surgery should be recommended to treat T2D in patients with class III obesity (BMI ≥40 kg/m2) and in those with class II obesity (BMI 35.0–39.9 kg/m2) when hyperglycemia is inadequately controlled by lifestyle and optimal medical therapy. Surgery should also be considered for patients with T2D and BMI 30.0–34.9 kg/m2 if hyperglycemia is inadequately controlled despite optimal treatment with either oral or injectable medications. These BMI thresholds should be reduced by 2.5 kg/m2 for Asian patients. CONCLUSIONS Although additional studies are needed to further demonstrate long-term benefits, there is sufficient clinical and mechanistic evidence to support inclusion of metabolic surgery among antidiabetes interventions for people with T2D and obesity. To date, the DSS-II guidelines have been formally endorsed by 45 worldwide medical and scientific societies. Health care regulators should introduce appropriate reimbursement policies.